Report Overview
[170+ Pages Research Report] Biological Therapies for Cancer Market to surpass USD 203.12 billion by 2031 from USD 79.96 billion in 2021 at a CAGR of 12.4% throughout the forecast period 2021-31
Product Overview
Cancer biological therapy, also known as immunotherapy or biotherapy is a high-level cancer treatment that makes use of living organisms. These life forms are derived from living cells or created in a laboratory to treat a cancer infection. Cancer biological therapies use the immune response of the body to fight cancer or to reduce the side effects of various cancer therapies. Immunotherapy, in general, has an indirect effect on cancer cells, whereas other biological therapies, such as antibodies, target cancer cells directly. The growing number of cancer cases and special cancer treatment facilities around the world are expected to aid in the growth of the global cancer biological therapy market.
Get More Information - Download Free Sample
Market Highlights
Global Biological Therapies for Cancer market is expected to project a notable CAGR of 12.4% in 2031.
Global Biological Therapies for Cancer to surpass USD 203.12 billion by 2031 from USD 79.96 billion in 2021 at a CAGR of 12.4% in the coming years, i.e., 2021-31. The factors driving the growth of the cancer biological therapy market include an increase in cancer incidence worldwide and earlier diagnosis, as well as a greater emphasis on research and development activities by key players.
Figure - Market Analysis of Global Biological Therapies for Cancer Market
Get More Information - Download Free Sample
Global Biological Therapies for Cancer: Segments
Monoclonal antibodies segment to grow with the highest CAGR during 2021-31
Global Biological Therapies for Cancer market is classified on the basis of Type into Monoclonal antibodies, Vaccines, Cancer growth blockers, Blood cell growth factors and Cytokines. Along with chemotherapy, radiation, and surgery, monoclonal antibody-based therapy is regarded as the primary component in cancer treatment. Because antibodies are highly specific, they directly target cancer cells while causing no harm to healthy cells and induce a long anti-tumor immune response. The growing global cancer burden will increase demand for cancer biological therapy and drive industry revenue. Furthermore, the global availability of monoclonal antibody-based immunotherapy treatments will have an impact on the demand for cancer biological therapy.
Hospital and retail pharmacies segment to grow with the highest CAGR during 2021-31
Based on application, global Biological Therapies for Cancer Market is fragmented into Specialized cancer treatment centers, Hospitals Pharmacies and Retail Pharmacies. Hospital and retail pharmacies segment held the greatest share of the vaccines technology market owing to its availability to the general public as they are under government surveillance.
Figure - Market Analysis of Global Biological Therapies for Cancer Market
Get More Information - Download Free Sample
Market Dynamics
Drivers
Increasing number of cancer patients and high alcohol consumption
The growing patient pool of cancer patients around the world is a key driving factor for the growth of the cancer biological therapy industry in the near future. High alcohol consumption and tobacco addiction have made significant contributions to the global cancer burden, increasing demand for biological therapies to treat cancer in the global market. Pouring funds into R&D activities and government initiatives to boost cancer research, successful ventures in clinical oncology, improved patient survival rate, and reduction in side effects of other cancer treatment therapies are thought to be major factors fueling growth in the cancer stem cell market.
Government initiatives and availability of generic medicines
Rising adoption of biosimilars in oncology, the availability of generic medicines for oncology treatment in the market due to patent expirations, rising disposable income and healthcare expenses, and rising awareness about oncology therapeutics and the benefits of biological therapies are all contributing to the growth of cancer biological therapy. Furthermore, good government approaches to cancer therapy in developed countries are expected to drive the global cancer biological therapy market.
Restraint
High cost associated with the market and side effects
The high treatment costs and side effects associated with cancer therapeutics may limit the growth of the cancer biological therapy market. Furthermore, the poor healthcare situation in several developing economies, such as India, and the fact that cancer biotherapy is not covered by medical insurance claims could stymie market growth.
Global Biological Therapies for Cancer: Key Players
- Bayer AG
Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis
- Amgen Inc.
- Celgene Corporation
- Eisai Co., Ltd.
- Hikma Pharmaceuticals PLC
- Incyte Corp
- Johnson & Johnson Services, Inc
- Otsuka Pharmaceutical Co., Ltd
- Pfizer, Inc
- Other Prominent Players
Global Biological Therapies for Cancer: Regions
Global Biological Therapies for Cancer market is segmented based on regional analysis into five major regions: North America, Latin America, Europe, Asia Pacific and the Middle East and Africa. The acceptance of a sedentary lifestyle, as well as unhealthy dietary habits, alcohol and drug abuse in North America is attributing to the rising incidence of cancer in the region.
Impact of Covid-19 on Biological Therapies for Cancer Market
The global spread of the COVID-19 pandemic has had a negative impact on the cancer biological therapy market, disrupting the spectrum of cancer care. During the pandemic, the industry saw a drop in sales of cancer biological drugs. Furthermore, the COVID-19 pandemic overburdened healthcare systems, causing many countries to suspend cancer diagnosis or screening and postpone cancer-related surgeries.
Get More Information - Download Free Sample
Global Biological Therapies for Cancer is further segmented by region into:
- North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United States and Canada
- Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil and Rest of Latin America
- Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey and Rest of Europe
- Asia Pacific Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia and Rest of APAC
- Middle East and Africa Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa and Rest of MENA
Global Biological Therapies for Cancer report also contains analysis on:
Biological Therapies for Cancer Segments:
- By Type
- Monoclonal antibodies
- Vaccines
- Cancer growth blockers
- Blood cell growth factors
- Cytokines
- By Application
- Specialized cancer treatment centers
- Hospitals Pharmacies
- Retail Pharmacies
- Biological Therapies for Cancer Dynamics
- Biological Therapies for Cancer Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies Involved in the Market
- Value Chain of the Market
- Market Drivers and Restraints
Biological Therapies for Cancer Market Report Scope and Segmentation
Biological Therapies for Cancer Segments:
- By Type
- Monoclonal antibodies
- Vaccines
- Cancer growth blockers
- Blood cell growth factors
- Cytokines
- By Application
- Specialized cancer treatment centers
- Hospitals Pharmacies
- Retail Pharmacies
- Biological Therapies for Cancer Dynamics
- Biological Therapies for Cancer Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies Involved in the Market
- Value Chain of the Market
- Market Drivers and Restraints
Biological Therapies for Cancer Market Report Scope and Segmentation
REPORT ATTRIBUTE |
DETAILS |
Market size value in 2021 |
USD 79.96 billion |
Revenue forecast in 2031 |
USD 203.12 billion |
Growth Rate |
CAGR of 12.4% from 2021 to 2031 |
Base year for estimation |
2020 |
Quantitative units |
Revenue in USD million and CAGR from 2021 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Type, Application and Region |
Regional scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA) |
Key companies profiled |
Bayer AG, Amgen Inc., Celgene Corporation, Eisai Co., Ltd., Hikma Pharmaceuticals PLC, Incyte Corp, Johnson & Johnson Services, Inc, Otsuka Pharmaceutical Co., Ltd, Pfizer, Inc and Other Prominent Players. |
Frequently Asked Questions (FAQ):
Biological Therapies for Cancer market size was estimated at USD 79.96 billion in 2021 and is expected to reach USD 203.12 billion in 2031.
Cancer biological therapy, also known as immunotherapy or biotherapy is a high-level cancer treatment that makes use of living organisms.
Monoclonal antibodies and Hospital and retail pharmacies accounted for the largest Biological Therapies for Cancer market share.
Key players: Bayer AG, Amgen Inc., Celgene Corporation, Eisai Co., Ltd., Hikma Pharmaceuticals PLC, Incyte Corp are the key players in the Biological Therapies for Cancer market.
The factors driving the growth of the cancer biological therapy market include an increase in cancer incidence worldwide and earlier diagnosis, as well as a greater emphasis on research and development activities by key players.